In AnaCardio’s Phase 2a segment of the GOAL-HF1 clinical study, the drug candidate AC01 demonstrated a favourable safety and tolerability profile. Exploratory measures of efficacy showed encouraging, consistent signs of rapid, sustained improvements in haemodynamics and cardiac structure and function over a 28-day treatment period.

“We are very pleased with AnaCardio’s encouraging Phase 2a data for AC01. It strengthens our confidence in the company’s ability to keep progressing its clinical development and tackle a significant unmet medical need among the large population of patients with heart failure and reduced ejection fraction,” says Mark Quick, Partner at Flerie and board member of AnaCardio.

Read AnaCardio’s full press release here: News - AnaCardio

Flerie’s holding in AnaCardio amounts to 13%.

For more information:
Mark Quick, Partner
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com